RT Journal Article
SR Electronic
T1 Protection conferred by vaccine plus previous infection (hybrid immunity) with vaccines of three different platforms during the Omicron variant period in Brazil
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.12.22273752
DO 10.1101/2022.04.12.22273752
A1 Cerqueira-Silva, Thiago
A1 de Araujo Oliveira, Vinicius
A1 Paixão, Enny S.
A1 Veras Florentino, Pilar Tavares
A1 Penna, Gerson O.
A1 Pearce, Neil
A1 Werneck, Guilherme L.
A1 Barreto, Maurício L.
A1 Boaventura, Viviane S.
A1 Barral-Netto, Manoel
YR 2022
UL http://medrxiv.org/content/early/2022/04/13/2022.04.12.22273752.abstract
AB Hybrid immunity (infection plus vaccination) provided high protection against infection and severe disease in the periods of delta and gamma variants of concern. However, the protection of hybrid immunity in the Omicron era remains unknown. We performed a test-negative study using Brazilian national databases between January 01 and March 22, 2022, a period of predominant circulation of the Omicron variant in Brazil. Hybrid immunity offered low protection against infection, with rapid waning, compared to unvaccinated with or without previous infection. For severe illness (hospitalisation or death), the protection, although already high for unvaccinated pre-infected increased regardless of the type of vaccine (Ad26.COV2.S, BNT162b2, ChAdOx-1 or CoronaVac).In conclusion, during the Omicron-dominant period in Brazil, hybrid immunity offered high protection against severe illness and low protection against infection.Competing Interest StatementMB-N reports grants from the Fazer o bem faz bem program from JBS VdAO, VB, MLB and MB-N are employees of Fiocruz, a federal public institu- tion, which manufactures Vaxzevria in Brazil, through a full technology transfer agree- ment with AstraZeneca. Fiocruz allocates all its manufactured products to the Ministry of Health for public health use. EPS is funded by the Wellcome Trust [Grant number 213589/Z/18/Z].Funding StatementMB-N reports grants from the Fazer o bem faz bem program from JBS. VdAO, VB, MLB, and MB-N are employees of Fiocruz, a federal public institution, which manufactures Vaxzevria in Brazil, through a full technology transfer agreement with AstraZeneca. Fiocruz allocates all its manufactured products to the Ministry of Health for public health use. EPS is funded by the Wellcome Trust [Grant number 213589/Z/18/Z].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data were pseudo-anonymized, with a common unique identifier provided by the Brazilian Ministry of Health. The research protocol was approved by the Brazilian National Commission in Research Ethics (CONEP) (approval no. 4.921.308).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOne of the study coordinators (MB-N) signed a term of responsibility on using each database made available by the Ministry of Health (MoH). Each member of the research team signed a term of confidentiality before accessing the data. Data was manipulated in a secure computing environment, ensuring protection against data leakage. The Brazilian National Commission in Research Ethics approved the research protocol (CONEP approval number 4.921.308). Our agreement with MoH for accessing the databases patently denies authorization of access to a third party. Any information for assessing the databases must be addressed to the Brazilian MoH at https://datasus.saude.gov.br/, and requests can be addressed to datasus{at}saude.gov.br. Herein we used anonymized secondary data following the Brazilian Personal Data Protection General Law (LGPD), but it is vulnerable to re-identification by third parties, as they contain dates of relevant health events regarding the same person. To protect the research participants' privacy, the approved Research Protocol (CONEP approval number 4.921.308) authorizes only the dissemination of aggregated data, such as the data presented here.